Генферон® Light

General characteristics. Structure:

Active ingredients: 10 000 ME of interferon alpha 2b human recombinant, 0,8 mg of taurine.

Excipients: dinatrium of an edetat a dihydrate, глицерол, dextran-35-45 thousand, polysorbate-80, sodium chloride, potassium chloride, sodium hydrophosphate, potassium dihydrophosphate, water for injections.

* Excipients are a part of Interferon Alpha 2b Human Recombinant (рчИФН-α2b) substance: sodium chloride, acetate sodium trihydrate, acetic acid ice, water for injections.

Pharmacological properties:

Pharmacodynamics. The drug Genferon® Light, drops nasal, renders antiviral, immunomodulatory, antiinflammatory, anti-proliferative, antibacterial action, has the local regenerating, membrane stabilizing and antioxidant properties.

Interferon the alpha blocks reproduction of viruses at a stage of synthesis of specific proteins and prevents infection of not infected cells of a mucous membrane of a nasal cavity, being the place of an invasion of activators and primary center of an inflammation at respiratory infections. Immunomodulatory action is shown by strengthening of cell-mediated reactions of immune system that increases efficiency of an immune response concerning alien agents. It is reached due to activation of CD8+ of T-killers, NK cells (natural killers), strengthening of a differentiation of V-lymphocytes and products of antibodies by them, activation of monocytic and macrophagic system and phagocytosis, and also increase in an expression of molecules of the main complex of histocompatability of the I type that increases probability of recognition of the infected cells cells of immune system.

Activation under the influence of interferon of the leukocytes which are contained in all layers of a mucous membrane provides their active participation in elimination of the pathological centers; besides, due to influence of interferon recovery of products of secretory immunoglobulin A is reached. The antibacterial effect is mediated by the reactions of immune system strengthened under the influence of interferon.

The taurine which is a part of drug normalizes metabolic processes in fabrics, promotes regeneration and more bystry recovery of a mucous membrane of the nasal cavity damaged by pathological process.

Pharmacokinetics. At intranasal use the drug Genferon® Light, drops nasal, creates high concentration of interferon in the center of an infection and renders the antiviral and immunostimulating effect expressed local.

System absorption of drug is insignificant, at intranasal introduction interferon human recombinant alpha 2b in a small amount is defined in pulmonary fabric and blood. In an organism biotransformation happens preferential in kidneys to an elimination half-life (T1/2) of 5,1 h. The small amount of drug getting to a system blood stream renders system immunomodulatory effect.

Indications to use:

Treatment of flu and other acute respiratory viral infections at children aged from 29 days up to 14 years.

Route of administration and doses:

At the first symptoms of a disease of Genferon® light dig in in a nose within 5 days.

To children from 29 days to 11 months 29 days - on 1 drop in each nasal course of 5 times a day (a single dose of 1 000 ME, a daily dose of 5 000 ME).

To children from 1 to 3 years - on 2 drops in each nasal course 3-4 times a day (a single dose of 2 000 ME, a daily dose of 6 000 - 8 000 ME).

To children from 3 to 14 years - on 2 drops in each nasal course of 4-5 times a day (a single dose of 2 000 ME, a daily dose of 8 000 - 10 000 ME).

Features of use:

Pregnancy and lactation. It is not used as drug is shown for use for children aged from 29 days up to 14 years.

After an instillation it is recommended to massage fingers nose wings within several minutes for hypodispersion of drug in a nasal cavity.

Influence on ability to manage vehicles and mechanisms. Influence of the drug Genferon® Light on performance of potentially dangerous types of activity requiring special attention and bystry reactions (control of vehicles, the machine equipment, etc.) was not studied.

Side effects:

Local allergic reactions (burning sensation, itch) are possible. These phenomena are reversible and disappear independently within 72 hours after drug phase-out. Continuation of treatment is possible only after consultation with the doctor.

Interaction with other medicines:

Simultaneous use of intranasal vasoconstrictive drugs as it causes additional dryness of a mucous membrane of a nasal cavity is not recommended.

Contraindications:

- Hypersensitivity to interferon alpha 2b or to other components of drug.

- Newborn from 0 to 28 days (in view of lack of clinical data).

Overdose:

Cases of overdose of the drug Genferon® Light are not registered so far.

Storage conditions:

In the dry, protected from light place at a temperature from 2 to 8 °C. Within the specified period of validity patients can store drug after opening within 7 weeks at a temperature from 2 to 8 °C. To store in the place, unavailable to children. A period of validity - 2 years. Not to apply after the expiry date specified on packaging.

Issue conditions:

According to the recipe

Packaging:

Drops nasal 10 000 ME/ml + 0,8 mg/ml. Packaging: on 10 ml in the bottles of dark glass which are hermetically corked by traffic jams with a running in aluminum caps. On each bottle paste the label. On 1 bottle complete with 1 nozzle dropper, together with the application instruction in a pack from a cardboard. On 10 ml in the bottles of dark glass which are hermetically corked by nozzles droppers. On each bottle paste the label. On 1 bottle together with the application instruction in a pack from a cardboard.